Zobrazeno 1 - 10
of 187
pro vyhledávání: '"Kazuto Nishio"'
Autor:
Satoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, Kyoichi Okishio, Morihito Okada, Ichiro Yoshino, Jiro Okami, Kazuhisa Takahashi, Norihiko Ikeda, Masayuki Tanahashi, Yuichi Tambo, Haruhiro Saito, Shinichi Toyooka, Hidetoshi Inokawa, Toyofumi Chen‐Yoshikawa, Toshihide Yokoyama, Tatsuro Okamoto, Noriko Yanagitani, Masahide Oki, Makoto Takahama, Kenji Sawa, Hirohito Tada, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Kazuto Nishio
Publikováno v:
Molecular Oncology, Vol 18, Iss 2, Pp 305-316 (2024)
The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC). Although the primary endpo
Externí odkaz:
https://doaj.org/article/5ef9670861fa45fda1c2e13f031a8170
Autor:
Hiroaki Kanemura, MD, MPH, PhD, Toshihide Yokoyama, MD, Ryu Nakajima, MD, PhD, Atsushi Nakamura, MD, PhD, Hiroaki Kuroda, MD, PhD, Yoshitaka Kitamura, MD, PhD, Hiroyasu Shoda, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihiro Miyata, MD, PhD, Tatsuro Okamoto, MD, PhD, Kyoichi Okishio, MD, PhD, Masahide Oki, MD, PhD, Yuichi Sakairi, MD, PhD, Toyofumi Fengshi Chen-Yoshikawa, MD, PhD, Tadashi Aoki, MD, Tatsuo Ohira, MD, PhD, Isao Matsumoto, MD, PhD, Kiyonobu Ueno, MD, PhD, Takuro Miyazaki, MD, PhD, Haruhisa Matsuguma, MD, PhD, Hideoki Yokouchi, MD, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Isamu Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100658- (2024)
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence
Externí odkaz:
https://doaj.org/article/6165423210284cf69a0cf2aac07b491b
Autor:
Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Masakatsu Tsurusaki, Takuya Nakai, Michiie Sakamoto, Kazuto Nishio, Masatoshi Kudo
Publikováno v:
Liver Cancer, Pp 1-21 (2023)
Introduction: Immunotherapy is becoming a promising approach for unresectable-hepatocellular carcinoma (HCC); the anti-tumor response is affected by the tumor microenvironment (TME). Although Wnt/β-catenin mutations are reported to cause non-inflame
Externí odkaz:
https://doaj.org/article/d0b2855877cb40998a23c23e48a72757
Autor:
Junko Tanizaki, MD, PhD, Hiroaki Kuroda, MD, PhD, Toshihide Yokoyama, MD, Makoto Takahama, MD, PhD, Hiroyasu Shoda, MD, PhD, Atsushi Nakamura, MD, PhD, Yoshitaka Kitamura, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihisa Kadota, MD, PhD, Kenji Sawa, MD, PhD, Kyoichi Okishio, MD, PhD, Morihito Okada, MD, PhD, Chihiro Suminaka, MS, Kenta Noda, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Kenji Chamoto, PhD, Tasuku Honjo, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100590- (2023)
Introduction: Perioperative treatment in NSCLC has gained marked attention with the introduction of immune checkpoint inhibitors. Such a paradigm shift has given us additional opportunities to evaluate potential biomarkers in patients with these cura
Externí odkaz:
https://doaj.org/article/3f386ee3f72d427a96a00d99cb19bacc
Autor:
Akiko Arimura, Kazuko Sakai, Kazuhisa Kaneshiro, Takafumi Morisaki, Saori Hayashi, Kimihisa Mizoguchi, Mai Yamada, Masaya Kai, Mayumi Ono, Kazuto Nishio, Masafumi Nakamura, Makoto Kubo
Publikováno v:
Cancers, Vol 16, Iss 6, p 1184 (2024)
Precise biomarkers for predicting the therapeutic efficacy of molecularly targeted drugs are limited at the protein level; thus, it has been important to broadly scrutinize individual cancer driver gene mutations for effective cancer treatments. Mult
Externí odkaz:
https://doaj.org/article/72197cabb61c4699a733aabc9b425a49
Autor:
Hanako Sato, Kosuke Murakami, Risa Fujishima, Tomoyuki Otani, Kazuko Sakai, Kazuto Nishio, Noriomi Matsumura
Publikováno v:
BMC Women's Health, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background Uterine angioleiomyoma is benign tumor that composed of smooth muscle cells and thick-walled vessels. It is a very rare condition reported to present as lower abdominal mass, accompanied by dysmenorrhea and hypermenorrhea. However
Externí odkaz:
https://doaj.org/article/485c60ab40e2476aa8604065e1576e85
Autor:
Toshiaki Takakura, MD, Hiroaki Kanemura, MD, MPH, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100523- (2023)
Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib a
Externí odkaz:
https://doaj.org/article/e7d70624992c46b5bea477f455c8785c
Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer
Autor:
Yujiro Hayashi, Kazutoshi Fujita, Kazuko Sakai, Shogo Adomi, Eri Banno, Satoshi Nojima, Eisuke Tomiyama, Makoto Matsushita, Taigo Kato, Koji Hatano, Atsunari Kawashima, Takafumi Minami, Eiichi Morii, Hirotsugu Uemura, Kazuto Nishio, Norio Nonomura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract During tumorigenesis, certain tissues are colonized by mutant clones with oncogenic driver mutations as precancer lesions. These mutations can facilitate clonal expansion and may contribute to malignant transformation. The molecular features
Externí odkaz:
https://doaj.org/article/92835b6f45b14269ba184ca2a398d544
Autor:
Toshiharu Sakurai, Marco A De Velasco, Kazuko Sakai, Tomoyuki Nagai, Hiroki Nishiyama, Kentaro Hashimoto, Hirotsugu Uemura, Hisato Kawakami, Kazuhiko Nakagawa, Hiroyuki Ogata, Kazuto Nishio, Masatoshi Kudo
Publikováno v:
Molecular Oncology, Vol 16, Iss 7, Pp 1493-1507 (2022)
Immune checkpoint inhibitors (ICIs) are widely used to treat various malignancies. Although the gut microbiome is known to influence the efficacy of ICIs on epithelial tumors, the functional interactions between gut taxa and colonic mucosa remain poo
Externí odkaz:
https://doaj.org/article/d953bfb730bd47ca942694545bf5a7ad
Autor:
Masato Maekawa, Terumi Taniguchi, Kazuto Nishio, Kazuko Sakai, Kazuyuki Matsushita, Kaname Nakatani, Takayuki Ishige, Makoto Ikejiri, Hiroshi Nishihara, Kuniko Sunami, Yasushi Yatabe, Kanako C. Hatanaka, Yutaka Hatanaka, Yoshihiro Yamamoto, Keita Fukuyama, Shinya Oda, Kayoko Saito, Mamoru Yokomura, Yuji Kubo, Hiroko Sato, Yoshinori Tanaka, Misa Fuchioka, Tadashi Yamasaki, Koichiro Matsuda, Kiyotaka Kurachi, Kazuhiro Funai, Satoshi Baba, Moriya Iwaizumi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract To implement precision oncology, analytical validity as well as clinical validity and utility are important. However, proficiency testing (PT) to assess validity has not yet been systematically performed in Japan. To investigate the quality
Externí odkaz:
https://doaj.org/article/7c2d199b86fd4cf6a1076280fcb3d386